DexCom Research Development vs Total Operating Expenses Analysis

DXCM Stock

USD 124.34 13.67 9.91%

DexCom financial indicator trend analysis is much more than just examining DexCom Inc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether DexCom Inc is a good investment. Please check the relationship between DexCom Research Development and its Total Operating Expenses accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

Research Development vs Total Operating Expenses

Research Development vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of DexCom Inc Research Development account and Total Operating Expenses. At this time, the significance of the direction appears to have almost identical trend.

The correlation between DexCom's Research Development and Total Operating Expenses is 0.97. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of DexCom Inc, assuming nothing else is changed. The correlation between historical values of DexCom's Research Development and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of DexCom Inc are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Research Development i.e., DexCom's Research Development and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.97

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most indicators from DexCom's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into DexCom Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

At this time, DexCom's Selling General Administrative is very stable compared to the past year. As of the 27th of April 2024, Tax Provision is likely to grow to about 177.3 M, while Issuance Of Capital Stock is likely to drop about 19.7 M.

DexCom fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Total Current Assets	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Common Stock	Property Plant Equipment	Other Liab	Short Term Investments	Short Long Term Debt Total
Total Assets		0.98	0.95	0.7	0.97	0.5	1.0	0.78	0.94	0.99	0.81	0.75	0.98	0.82	0.96	0.81	0.97	0.66	0.67	0.99	0.96	0.81	0.98	0.94	0.98	0.99
Total Stockholder Equity	0.98		0.89	0.75	0.98	0.56	0.98	0.67	0.89	0.97	0.73	0.8	0.95	0.72	0.92	0.72	0.94	0.72	0.76	0.96	0.9	0.72	0.94	0.97	0.97	0.97
Net Debt	0.95	0.89		0.46	0.88	0.35	0.93	0.87	0.94	0.96	0.9	0.63	0.97	0.89	0.97	0.89	0.92	0.56	0.45	0.97	0.98	0.89	0.96	0.86	0.96	0.94
Cash	0.7	0.75	0.46		0.81	0.58	0.75	0.32	0.51	0.62	0.24	0.6	0.57	0.44	0.52	0.31	0.73	0.51	0.87	0.67	0.52	0.31	0.58	0.69	0.64	0.73
Cash And Short Term Investments	0.97	0.98	0.88	0.81		0.55	0.99	0.68	0.85	0.93	0.68	0.74	0.91	0.75	0.88	0.68	0.97	0.65	0.79	0.96	0.87	0.68	0.9	0.94	0.97	0.98
Common Stock Shares Outstanding	0.5	0.56	0.35	0.58	0.55		0.52	0.17	0.42	0.48	0.06	0.55	0.44	0.31	0.38	0.34	0.45	0.54	0.78	0.45	0.38	0.34	0.44	0.49	0.48	0.49
Total Current Assets	1.0	0.98	0.93	0.75	0.99	0.52		0.76	0.91	0.97	0.76	0.73	0.96	0.81	0.94	0.77	0.98	0.64	0.71	0.99	0.94	0.77	0.95	0.94	0.98	1.0
Other Current Liab	0.78	0.67	0.87	0.32	0.68	0.17	0.76		0.75	0.77	0.85	0.23	0.8	0.84	0.83	0.84	0.83	0.13	0.18	0.83	0.89	0.84	0.81	0.69	0.76	0.79
Total Current Liabilities	0.94	0.89	0.94	0.51	0.85	0.42	0.91	0.75		0.97	0.88	0.79	0.98	0.86	0.97	0.93	0.85	0.74	0.48	0.94	0.95	0.93	0.97	0.84	0.9	0.92
Property Plant And Equipment Net	0.99	0.97	0.96	0.62	0.93	0.48	0.97	0.77	0.97		0.85	0.79	1.0	0.81	0.97	0.86	0.93	0.7	0.6	0.98	0.97	0.86	1.0	0.92	0.96	0.97
Retained Earnings	0.81	0.73	0.9	0.24	0.68	0.06	0.76	0.85	0.88	0.85		0.51	0.89	0.77	0.92	0.88	0.76	0.45	0.12	0.84	0.91	0.88	0.88	0.76	0.79	0.78
Accounts Payable	0.75	0.8	0.63	0.6	0.74	0.55	0.73	0.23	0.79	0.79	0.51		0.76	0.47	0.69	0.58	0.61	0.96	0.69	0.7	0.64	0.58	0.75	0.7	0.71	0.71
Non Current Assets Total	0.98	0.95	0.97	0.57	0.91	0.44	0.96	0.8	0.98	1.0	0.89	0.76		0.83	0.99	0.9	0.92	0.68	0.54	0.98	0.98	0.9	1.0	0.91	0.95	0.96
Non Currrent Assets Other	0.82	0.72	0.89	0.44	0.75	0.31	0.81	0.84	0.86	0.81	0.77	0.47	0.83		0.85	0.88	0.82	0.45	0.33	0.87	0.87	0.88	0.81	0.66	0.8	0.85
Other Assets	0.96	0.92	0.97	0.52	0.88	0.38	0.94	0.83	0.97	0.97	0.92	0.69	0.99	0.85		0.89	0.91	0.64	0.48	0.96	0.97	0.89	0.98	0.92	0.94	0.94
Common Stock Total Equity	0.81	0.72	0.89	0.31	0.68	0.34	0.77	0.84	0.93	0.86	0.88	0.58	0.9	0.88	0.89		0.75	0.52	0.23	0.85	0.92	1.0	0.89	0.68	0.76	0.8
Non Current Liabilities Total	0.97	0.94	0.92	0.73	0.97	0.45	0.98	0.83	0.85	0.93	0.76	0.61	0.92	0.82	0.91	0.75		0.49	0.65	0.98	0.93	0.75	0.93	0.91	0.96	0.99
Other Current Assets	0.66	0.72	0.56	0.51	0.65	0.54	0.64	0.13	0.74	0.7	0.45	0.96	0.68	0.45	0.64	0.52	0.49		0.62	0.61	0.54	0.52	0.66	0.64	0.64	0.62
Other Stockholder Equity	0.67	0.76	0.45	0.87	0.79	0.78	0.71	0.18	0.48	0.6	0.12	0.69	0.54	0.33	0.48	0.23	0.65	0.62		0.6	0.45	0.23	0.54	0.7	0.67	0.67
Total Liab	0.99	0.96	0.97	0.67	0.96	0.45	0.99	0.83	0.94	0.98	0.84	0.7	0.98	0.87	0.96	0.85	0.98	0.61	0.6		0.98	0.85	0.98	0.91	0.97	0.99
Property Plant And Equipment Gross	0.96	0.9	0.98	0.52	0.87	0.38	0.94	0.89	0.95	0.97	0.91	0.64	0.98	0.87	0.97	0.92	0.93	0.54	0.45	0.98		0.92	0.99	0.87	0.93	0.95
Common Stock	0.81	0.72	0.89	0.31	0.68	0.34	0.77	0.84	0.93	0.86	0.88	0.58	0.9	0.88	0.89	1.0	0.75	0.52	0.23	0.85	0.92		0.89	0.68	0.76	0.8
Property Plant Equipment	0.98	0.94	0.96	0.58	0.9	0.44	0.95	0.81	0.97	1.0	0.88	0.75	1.0	0.81	0.98	0.89	0.93	0.66	0.54	0.98	0.99	0.89		0.91	0.94	0.96
Other Liab	0.94	0.97	0.86	0.69	0.94	0.49	0.94	0.69	0.84	0.92	0.76	0.7	0.91	0.66	0.92	0.68	0.91	0.64	0.7	0.91	0.87	0.68	0.91		0.94	0.92
Short Term Investments	0.98	0.97	0.96	0.64	0.97	0.48	0.98	0.76	0.9	0.96	0.79	0.71	0.95	0.8	0.94	0.76	0.96	0.64	0.67	0.97	0.93	0.76	0.94	0.94		0.98
Short Long Term Debt Total	0.99	0.97	0.94	0.73	0.98	0.49	1.0	0.79	0.92	0.97	0.78	0.71	0.96	0.85	0.94	0.8	0.99	0.62	0.67	0.99	0.95	0.8	0.96	0.92	0.98

Click cells to compare fundamentals

DexCom Account Relationship Matchups

High Positive Relationship

Total Current Assets	+ 1.0	Total Assets
Short Long Term Debt Total	+ 1.0	Total Current Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant Equipment	+ 1.0	Property Plant And Equipment Net
Property Plant Equipment	+ 1.0	Non Current Assets Total
Common Stock	+ 1.0	Common Stock Total Equity

High Negative Relationship

Not Found

DexCom fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.4B	4.3B	4.9B	5.4B	6.3B	6.6B
Total Stockholder Equity	882.6M	1.8B	2.3B	2.1B	2.1B	2.2B
Net Debt	699.5M	1.0B	769.2M	1.4B	2.0B	2.1B
Cash	446.2M	817.6M	1.1B	642.3M	566.3M	594.6M
Cash And Short Term Investments	1.5B	2.7B	2.7B	2.5B	2.7B	2.9B
Common Stock Shares Outstanding	369.2M	390M	428.8M	427.5M	425.5M	246.4M
Liabilities And Stockholders Equity	2.4B	4.3B	4.9B	5.4B	6.3B	6.6B
Total Current Assets	2.0B	3.4B	3.7B	3.7B	4.4B	4.6B
Other Current Liab	88.5M	432.1M	125.2M	134.3M	1.2B	1.3B
Total Current Liabilities	360.2M	614.1M	720.8M	1.8B	1.6B	1.6B
Property Plant And Equipment Net	392.8M	608.6M	889.9M	1.1B	1.2B	1.2B
Retained Earnings	(695.7M)	(202.1M)	(47.4M)	479.9M	1.0B	1.1B
Accounts Payable	256.4M	163.3M	573M	901.8M	276.4M	290.2M
Non Current Assets Total	425.6M	865.7M	1.2B	1.7B	1.8B	1.9B
Non Currrent Assets Other	14.2M	21.4M	(4.5M)	28.1M	36.5M	38.3M
Other Assets	14.2M	237.8M	220.8M	369.3M	424.7M	445.9M
Non Current Liabilities Total	1.2B	1.8B	1.9B	1.4B	2.6B	2.8B
Other Current Assets	30M	53.9M	81.6M	192.6M	49.3M	25.1M
Other Stockholder Equity	1.6B	2.0B	2.3B	1.7B	1.1B	1.1B
Total Liab	1.5B	2.5B	2.6B	3.3B	4.2B	4.4B
Property Plant And Equipment Gross	392.8M	608.6M	801.8M	1.1B	1.7B	1.8B
Accumulated Other Comprehensive Income	2.3M	3.2M	500K	(11.6M)	(16.7M)	(15.9M)
Property Plant Equipment	321.3M	515.3M	889.9M	1.1B	1.3B	1.4B
Other Liab	5.7M	80.9M	90M	68.7M	79.0M	83.0M
Short Term Investments	1.1B	1.9B	1.7B	1.8B	2.2B	2.3B
Short Long Term Debt Total	1.1B	1.8B	1.8B	2.1B	2.6B	2.7B
Long Term Debt	1.1B	1.7B	1.7B	1.2B	2.4B	2.6B
Net Receivables	286.3M	428.5M	514.3M	713.3M	987.5M	1.0B
Inventory	119.8M	234.7M	357.3M	306.7M	559.6M	587.6M
Short Term Debt	13.6M	16.5M	20.5M	793.1M	21.1M	20.0M
Current Deferred Revenue	1.7M	2.2M	2.1M	10.1M	18.4M	19.3M
Net Tangible Assets	864M	1.8B	2.2B	2.1B	2.5B	2.6B
Good Will	18.6M	19.3M	26.5M	25.7M	25.2M	14.4M
Retained Earnings Total Equity	(695.7M)	(202.1M)	(47.4M)	479.9M	551.9M	579.5M
Capital Surpluse	1.7B	2.1B	2.5B	2.3B	2.6B	1.5B

Pair Trading with DexCom

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.

Moving against DexCom Stock

0.78	DNA	Ginkgo Bioworks Holdings Financial Report 8th of May 2024	Pair Corr
0.62	IDXX	IDEXX Laboratories Financial Report 7th of May 2024	Pair Corr
0.61	GH	Guardant Health Financial Report 14th of May 2024	Pair Corr
0.47	CTSO	Cytosorbents Crp Financial Report 7th of May 2024	Pair Corr
0.46	GMED	Globus Medical Financial Report 2nd of May 2024	Pair Corr

The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.

The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:

How To Invest In DexCom

Details

Is DexCom Stock a good investment?

Details

What is DexCom's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for DexCom Stock analysis

When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.

	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Share Portfolio Track or share privately all of your investments from the convenience of any device

Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.81

Earnings Share

1.34

Revenue Per Share

9.384

Quarterly Revenue Growth

0.269

Return On Assets

0.0641

The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

DexCom Research Development vs Total Operating Expenses Analysis

Research Development vs Total Operating Expenses

Research Development vs Total Operating Expenses Correlation Analysis

Correlation Coefficient

Research Development

Total Operating Expenses

DexCom fundamental ratios Correlations

DexCom Account Relationship Matchups

High Positive Relationship

High Negative Relationship

DexCom fundamental ratios Accounts

Pair Trading with DexCom

Moving against DexCom Stock

Complementary Tools for DexCom Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY